PHR
Phreesia, Inc. · Healthcare · Health Information Services
At close
$12.41
+$0.08 (+0.65%) Close
Pre-market $12.36 −$0.05 (−0.40%) 8:01 AM ET
Prev close $12.33
Open $12.31
Day high $12.41
Day low $12.31
Volume 1,781,921
Avg vol 1,819,376
Mkt cap
$743.34M
P/E ratio
-124.10
FY Revenue
$463.21M
EPS
-0.10
Gross Margin
85.13%
Sector
Healthcare
AI report sections
PHR
Phreesia, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−4% (Below avg)
Vol/Avg: 0.96×
RSI
39.10 (Weak)
Weak (30–40)
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.03 Signal: 0.03
Short-Term
+0.13 (Strong)
MACD: -0.88 Signal: -1.02
Long-Term
+0.05 (Strong)
MACD: -1.79 Signal: -1.83
Intraday trend score 48.00

Latest news

PHR 12 articles Positive: 1 Neutral: 1 Negative: 0
Neutral Benzinga • Rishabh Mishra
Stock Market Today: Dow Futures Pare Losses, S&P 500, Nasdaq Gain— Carvana, Confluent, Toll Brothers In Focus (UPDATED)

U.S. stock futures advanced on Monday, with investors anticipating the Federal Reserve's upcoming interest rate decision and several key corporate earnings reports. Markets showed mixed performance with communication and technology stocks performing well.

CVNA CFLT TOL PHR stock market futures Federal Reserve interest rates
Sentiment note

Slightly up 1.95%, scheduled to report earnings with expected 2 cents per share

Positive The Motley Fool • Cory Renauer
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase

Capricorn Fund Managers Ltd acquired 484,500 shares of Phreesia, valued at $11.4 million, representing 3.8% of their reportable assets under management. The investment comes as Phreesia reaches a milestone of first quarterly net income and plans to expand payment solutions.

PHR WAY TARS MSFT healthcare SaaS investment patient intake
Sentiment note

Company achieved first quarterly net income, planning business expansion, and attracting significant institutional investment

Unknown Benzinga • Benzinga Insights
A Glimpse Into The Expert Outlook On Phreesia Through 6 Analysts

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:PHR) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.83, a high estimate of $34.00, and a low estimate of $28.00. A decline of 4.79% from the prior average price target is evident in the current average. Decoding Analyst Ratings: A Detailed Look In examining recent analyst actions, we gain insights into how financial experts perceive Phreesia. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jailendra Singh Truist Securities Maintains Buy $29.00 $29.00 Jailendra Singh Truist Securities Lowers Buy $29.00 $35.00 Richard Close Canaccord Genuity Lowers Buy $34.00 $37.00 Jeff Garro Stephens & Co. Maintains Overweight $28.00 $28.00 Joe Goodwin JMP Securities Maintains Market Outperform $30.00 $30.00 Ryan MacDonald Needham Maintains Buy $29.00 $29.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Phreesia. This information provides a snapshot of how analysts perceive the current state of the company. Rating: ...Full story available on Benzinga.com

PHR Analyst Ratings
Unknown Zacks Investment Research • Sanghamitra Saha
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).

APDN PHR BDSX YOU
Unknown Zacks Investment Research • Nalak Das
5 Medical Info Systems Stock to Buy for a Stable Portfolio

We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

PHR LUNG HIMS ENOV
Unknown Zacks Investment Research • Zacks Equity Research
Here's Why Phreesia (PHR) is Poised for a Turnaround After Losing -18.25% in 4 Weeks

Phreesia (PHR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

PHR
Unknown Benzinga • Benzinga Insights
Assessing Phreesia: Insights From 12 Financial Analysts

Across the recent three months, 12 analysts have shared their insights on Phreesia (NYSE:PHR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 6 3 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 6 3 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.0, a high estimate of $37.00, and a low estimate of $23.00. Observing a 3.06% increase, the current average has risen from the previous average price target of $28.14. Diving into Analyst Ratings: An In-Depth Exploration An in-depth analysis of recent analyst actions unveils how financial experts perceive Phreesia. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Ryan MacDonald Needham Maintains Buy $29.00 $29.00 Jeff Garro Stephens & Co. Maintains Overweight $28.00 - Sean Dodge RBC Capital Maintains Sector Perform $23.00 - Joe Goodwin JMP Securities Raises Market Outperform $30.00 $28.00 Joseph Vruwink Baird Raises Outperform $31.00 $30.00 Ryan MacDonald Needham Maintains Buy $29.00 - Sean Dodge RBC Capital Raises Sector Perform $23.00 $17.00 John Ransom Raymond James Raises Outperform $30.00 $25.00 Joe Goodwin JMP Securities Maintains Market Outperform $28.00 - Robert Simmons DA Davidson Maintains Neutral $32.00 $32.00 Richard Close Canaccord Genuity Raises Buy $37.00 $36.00 Joe Goodwin JMP Securities Maintains Market Outperform $28.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', ...Full story available on Benzinga.com

PHR Analyst Ratings
Unknown Zacks Investment Research • Zacks Equity Research
Compared to Estimates, Phreesia (PHR) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Phreesia (PHR) give a sense of how its business performed in the quarter ended April 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PHR
Unknown Zacks Investment Research • Zacks Equity Research
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates

Phreesia (PHR) delivered earnings and revenue surprises of 31.37% and 0.20%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?

PHR NVTAQ
Unknown Zacks Investment Research • Zacks Equity Research
Unlocking Q1 Potential of Phreesia (PHR): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Phreesia (PHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended April 2024.

PHR
Unknown Zacks Investment Research • Zacks Equity Research
Talkspace, Inc. (TALK) Reports Q1 Loss, Tops Revenue Estimates

Talkspace (TALK) delivered earnings and revenue surprises of 50% and 2.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

TALK PHR
Unknown Zacks Investment Research • Zacks Equity Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

UHS PHR
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal